Principal Financial Group
CASC

Principal Financial Group’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Principal Financial Group’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,687
Closed -$20K – 2235
2016
Q1 		$20K Hold
2,687
– – ﹤0.01% 2158
2015
Q4 		$36K Sell
2,687
-198
-7% -$3.41K ﹤0.01% 2169
2015
Q3 		$47K Buy
+2,885
New +$59.1K ﹤0.01% 2144
2014
Q4 		– Sell
-3,965
Closed -$46K – 2253
2014
Q3 		$46K Buy
+3,965
New +$60.6K ﹤0.01% 2192

Other funds holding CASC

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Principal Financial Group's CASC Position: Q2 2016 in Review

Principal Financial Group sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2016, closing a stake of 2,687 shares — an estimated $20K sold.

Principal Financial Group first reported a position in CASC in Q3 2014 and held it in 4 quarters. The position peaked at $47K in Q3 2015. 75 funds tracked by Wall St. Rank hold CASC as of Q2 2016.

  • Principal Financial Group reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Principal Financial Group sold 2,687 Cascadian Therapeutics, Inc. shares in Q2 2016, an estimated $20K.
  • Principal Financial Group first reported a position in Cascadian Therapeutics, Inc. in Q3 2014 and held it in 4 quarters.
  • Principal Financial Group's Cascadian Therapeutics, Inc. position peaked at $47K in Q3 2015.
  • 75 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2016.

Based on Principal Financial Group's 13F filing for Q2 2016, filed 9 Aug 2016.